173 related articles for article (PubMed ID: 28121597)
1. Zinplava Tackles Toxins Of Hard-to-Treat C. Difficile.
Morrow T
Manag Care; 2017 Jan; 26(1):30-31. PubMed ID: 28121597
[TBL] [Abstract][Full Text] [Related]
2. Bezlotoxumab: First Global Approval.
Markham A
Drugs; 2016 Dec; 76(18):1793-1798. PubMed ID: 27905086
[TBL] [Abstract][Full Text] [Related]
3. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
Villafuerte Gálvez JA; Kelly CP
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
[TBL] [Abstract][Full Text] [Related]
5. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
[TBL] [Abstract][Full Text] [Related]
7. ▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.
Drug Ther Bull; 2018 May; 56(5):57-60. PubMed ID: 29760164
[No Abstract] [Full Text] [Related]
8. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
9. Bezlotoxumab (Zinplava) for prevention of recurrent Clostridium difficile infection.
Med Lett Drugs Ther; 2017 Mar; 59(1517):49-50. PubMed ID: 28323808
[No Abstract] [Full Text] [Related]
10. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
[TBL] [Abstract][Full Text] [Related]
11. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
12. [Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA
Kinoshita K
Nihon Yakurigaku Zasshi; 2018; 152(1):39-50. PubMed ID: 29998951
[TBL] [Abstract][Full Text] [Related]
13. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
14. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
[TBL] [Abstract][Full Text] [Related]
15. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
16. Bezlotoxumab for the Prevention of
Chahine EB; Cho JC; Worley MV
Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
[TBL] [Abstract][Full Text] [Related]
17. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
[TBL] [Abstract][Full Text] [Related]
18. Bezlotoxumab for the prevention of Clostridium difficile recurrence.
Couture-Cossette A; Carignan A; Ilangumaran S; Valiquette L
Expert Opin Biol Ther; 2017 Nov; 17(11):1439-1445. PubMed ID: 28805081
[TBL] [Abstract][Full Text] [Related]
19. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
[TBL] [Abstract][Full Text] [Related]
20. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
Deeks ED
Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]